Soligenix presenting at 2015 Chemical and Biological Defense Conference
Two vaccine candidates for ricin intoxication and anthrax toxin are currently in pre-clinical trials along with a treatment option candidate for melioidosis.
RiVax, a ricin intoxication vaccine candidate, has shown to be effective in non-human primates and also has been effective in aiding the development of ricin antibodies in healthy volunteers. The compound also has shown that it is not toxic to those receiving a dose of the vaccine. Antibodies were reported to last 127 days after three doses.
Currently no vaccine has been approved for use by the U.S. Food and Drug Administration for ricin toxicity.
The SGX943 treatment is an Innate Defense Regulator (IDR) that has been shown to have anti-inflammatory and anti-infective properties by facilitating an enhanced immunological response. It addresses growing concerns of anti-bacterial resistance by not interacting with the bacteria directly. In early studies, it has shown to increase survivability for a broad range of bacterial infections.
VeloThrax has shown in animal models that it is effective against anthrax toxins and has developed antibodies in those given doses for up to a year without booster shots. The candidate was originally developed by Dr. John Collier and others from Harvard University.
An oral presentation will take place at 11:20 a.m. EDT May 14 regarding anti-bacterial resistance and the use of IDRs. Poster presentations of the two vaccine candidates are set to take place beginning at 6 p.m. on May 12.